Blood levels of omega-6 fatty acids and coronary heart disease : a systematic review and metaanalysis of observational epidemiology
Individual omega-6 polyunsaturated fatty acids (PUFAs), principally linoleic acid (LA) and arachidonic acid (AA), may have differential impacts on cardiovascular risk. We aimed to summarize the up-to-date epidemiology evidence on the relationship between blood levels of omega-6 PUFAs and the risk of coronary heart disease (CHD). Population-based studies determining PUFA levels in blood were identified until May 2021 in PubMed, Embase, Web of Science, and Cochrane Library. Random-effects meta-analyses of cohorts comparing the highest versus lowest category were conducted to combine study-specific risk ratios (RRs) with 95% confidence intervals (CIs). Blood levels of omega-6 PUFAs were compared between the CHD case and non-case, presented as a weight mean difference (WMD). Twenty-one cohorts and eleven case-control studies were included. The WMD was -0.71 (95% CI: -1.20, -0.21) for LA and 0.08 (95% CI: -0.28, 0.43) for AA. LA levels were inversely associated with total CHD risk (RR: 0.85, 95% CI: 0.71, 1.00), but not AA. Each one-SD increase in LA levels resulted in 10% reductions in the risk of fatal CHD (RR: 0.90, 95% CI: 0.86, 0.95), but not in non-fatal CHD. Such findings highlight that the current recommendation for optimal intakes of omega-6 PUFAs (most LA) may offer a coronary benefit in primary prevention.Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2022.2056867.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Critical reviews in food science and nutrition - 63(2023), 26 vom: 01., Seite 7983-7995 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Xiao-Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arachidonic acid |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10408398.2022.2056867 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339103043 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339103043 | ||
| 003 | DE-627 | ||
| 005 | 20231226002146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10408398.2022.2056867 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339103043 | ||
| 035 | |a (NLM)35380474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Xiao-Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood levels of omega-6 fatty acids and coronary heart disease |b a systematic review and metaanalysis of observational epidemiology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Individual omega-6 polyunsaturated fatty acids (PUFAs), principally linoleic acid (LA) and arachidonic acid (AA), may have differential impacts on cardiovascular risk. We aimed to summarize the up-to-date epidemiology evidence on the relationship between blood levels of omega-6 PUFAs and the risk of coronary heart disease (CHD). Population-based studies determining PUFA levels in blood were identified until May 2021 in PubMed, Embase, Web of Science, and Cochrane Library. Random-effects meta-analyses of cohorts comparing the highest versus lowest category were conducted to combine study-specific risk ratios (RRs) with 95% confidence intervals (CIs). Blood levels of omega-6 PUFAs were compared between the CHD case and non-case, presented as a weight mean difference (WMD). Twenty-one cohorts and eleven case-control studies were included. The WMD was -0.71 (95% CI: -1.20, -0.21) for LA and 0.08 (95% CI: -0.28, 0.43) for AA. LA levels were inversely associated with total CHD risk (RR: 0.85, 95% CI: 0.71, 1.00), but not AA. Each one-SD increase in LA levels resulted in 10% reductions in the risk of fatal CHD (RR: 0.90, 95% CI: 0.86, 0.95), but not in non-fatal CHD. Such findings highlight that the current recommendation for optimal intakes of omega-6 PUFAs (most LA) may offer a coronary benefit in primary prevention.Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2022.2056867 | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arachidonic acid | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a coronary heart disease | |
| 650 | 4 | |a linoleic acid | |
| 650 | 4 | |a omega-6 PUFAs | |
| 650 | 7 | |a Fatty Acids, Omega-3 |2 NLM | |
| 650 | 7 | |a Fatty Acids, Omega-6 |2 NLM | |
| 650 | 7 | |a Fatty Acids, Unsaturated |2 NLM | |
| 700 | 1 | |a Liu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Wei-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ze-Wang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shuang-Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhi-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Bo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in food science and nutrition |d 1980 |g 63(2023), 26 vom: 01., Seite 7983-7995 |w (DE-627)NLM012713538 |x 1549-7852 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:26 |g day:01 |g pages:7983-7995 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10408398.2022.2056867 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 26 |b 01 |h 7983-7995 | ||